Funding Expensive Treatments: Weighing the Trade Offs

A new therapy costs an enormous amount per patient. It might add months, or it might add years, and the evidence is thinner than anyone would like. A family is on the news asking why the government will not pay for it. You have five minutes to tell an assessor what you think.

There are two easy answers and both are weak. One is that you cannot put a price on a human life. The other is a cold sum where the money obviously goes further elsewhere. The first refuses to engage with the problem. The second engages with it and forgets there is a person in it.

The question is not about money, it is about what the money was going to do

Opportunity cost is the whole station. A public health budget is finite, so funding one thing is not a decision to spend, it is a decision to not spend somewhere else. That somewhere else has patients in it too. They are just anonymous, so nobody films them.

If you say that clearly and early, the rest of your answer has somewhere to stand. If you never say it, you end up arguing about whether the drug is worth it in the abstract, which nobody can settle in five minutes.

Australia funds medicines through a national subsidy scheme with an expert advisory committee that weighs clinical effectiveness against cost before a medicine is listed. Knowing that the process exists is enough. You will not be quizzed on its internal workings, and inventing detail is worse than admitting you do not know it. This is true of most ethical stations in Australian MMIs: the reasoning carries the marks, not the trivia.

The questions a funding decision actually turns on

You do not need health economics. You need the handful of questions that any serious person would ask before writing the cheque.

• Does it work, and how much? There is a real difference between a therapy that cures, one that extends life meaningfully, and one that moves a number on a scan without the patient feeling any better.
• Compared with what? A benefit is always relative to the current standard of care, not to doing nothing.
• How confident are we? Small trials, short follow up and substitute endpoints all make the promised benefit less certain, and uncertainty has a cost of its own.
• What gets displaced? Name something plausible: nursing hours, a screening programme, mental health services, rural outreach. Vagueness here is what makes opportunity cost sound theoretical.
• Is the price fixed? Prices are negotiated, not handed down. Refusing to fund at one price is not the same as refusing to fund.
• What precedent does this set? The next therapy will be priced knowing what you did with this one.

Three or four of those, used properly, will put you well ahead of a candidate who lists all six and develops none.

The human side is not decoration

There is a well described pull in ethics towards rescuing the person in front of us, even at costs we would never accept for people we cannot see. It is not irrational. A society that shrugs at an identifiable dying child is not one most of us want to live in, and the willingness to rescue is part of what makes health systems trusted rather than merely efficient.

But it pulls hard enough to distort. The visible patient has a name, a face and a fundraiser. The patients who lose the displaced service have none of that. A strong answer holds both facts at once: the pull is real and worth respecting, and it is also a reason to be careful, because the people it disadvantages will never be interviewed.

Give the invisible patients one sentence of substance. Not the diffuse others in the system, but something concrete you can picture. That single move is what separates an answer that weighs from an answer that calculates.

The traps

You cannot put a price on a life

Every health system already does, implicitly, every day it decides what to fund. Saying the sentence and stopping tells the assessor you would like the dilemma to go away. If you believe cost should not be a factor, you owe them the consequence: unlimited funding for anything a patient wants means someone else's treatment is cut without anyone deciding to cut it.

The calculator answer

Technically fine, humanly unnerving. If your conclusion is that the money is better spent elsewhere, say what that means for the family who wanted the drug, and what you would still offer them: honest information, good symptom control, trial access if any exists, and a clinician who does not disappear once the answer is no.

Blaming the manufacturer and stopping

Pricing is a legitimate part of the discussion and the incentives are worth naming. It is not the whole answer, because the decision still has to be made this year with the price as it stands. Use it as one factor, not as an exit.

A structure you can run in five minutes

• Frame it as an allocation decision, not a spending decision, in your first fifteen seconds.
• Give the case for funding properly, including the rescue argument, before you argue against it.
• Ask the effectiveness and certainty questions out loud, and say what evidence would change your view.
• Name one concrete thing the money would otherwise fund.
• Reach for a middle path if one honestly exists: fund at a negotiated price, fund with a data collection condition, fund for the subgroup who benefit most.
• Land somewhere, then say who pays for your landing and what you owe them.

The middle path deserves a warning. Conditional funding is a real mechanism, not a dodge, but only if you say what the condition is and what happens when it is not met. Otherwise it is fence sitting with better vocabulary.

When they make it personal

A common follow up is some version of what if it were your sister. Do not pretend you would be neutral. Nobody is neutral about their own family, and claiming otherwise reads as false.

The honest answer is that you would fight for her, you would want every option, and that is precisely why the decision is not made by the person at the bedside. Systems exist so that advocacy and allocation sit in different hands. Saying that shows insight rather than coldness, and it answers the question instead of deflecting it.

How to practise it

Take one prompt and answer it twice. Once arguing to fund, once arguing not to, both times naming the cost of your position. You will find the same six questions carry both arguments, which is exactly the point. If the format itself is still new to you, start with our overview of what an MMI is in Australia and New Zealand, and check your university's current admissions page for the format it actually runs.

The hard part is doing it in five minutes with a timer running and someone challenging your figures. MasterMed's live AI interviewer runs timed MMI stations and marks you against a rubric, so you can hear whether your funding answer sounded thoughtful or accountant shaped. The first speaking station is free on the trial, no card, and the trial never converts by itself.

Rubrics differ between schools, and our guide to how MMI scoring works in Australia sets out the domains that recur. None of them reward the right verdict on drug funding, because there is no right verdict. They reward someone who can hold a budget and a bedside in mind at the same time, which is most of what the job actually asks of you.